vVARDIS
Swiss dental medtech selling dentists Curodont, a peptide-based treatment for early carious lesions.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
๐๏ธ Deep Dive
Nscale, vVARDIS, Kry โ IPO scrutiny and digital health consolidation โ Daily News November 13, 2026
Listen to the episodeAbout vVARDIS
vVARDIS is a dental medtech company based in Zug, Switzerland, led by its co-CEOs and founders Haley and Goly Abivardi, both dentists; the holding company was incorporated in 2020. Under the Curodont brand it sells dentists a peptide-based treatment that repairs early carious lesions without drilling or injections: in the US, where Henry Schein has distributed it exclusively since early 2024, the company reports about three million teeth treated and use in nearly 20% of general practices. After $85 million from OrbiMed in 2025, on 27 April 2026 a minority investment by Apollo-managed funds valued it above $1 billion. On 12 November 2026 it priced its NYSE listing (ticker VVVV): 9,722,223 shares at $18, below the initial $21-24 range, for about $175 million gross, with closing expected on 16 November. Revenue for the twelve months to 30 June 2026 was $50 million.
The Story
Founded by dentist sisters Haley and Goly Abivardi; the Swiss holding company was incorporated in 2020.
How vVARDIS works
Business Model
Sales of dental medtech products to professionals through distributors.
Revenue Model
Product sales.
Products & Services
Key Products
- Curodont Repair Fluoride Plus
Core Use Cases
- Non-invasive treatment of early cavities
Market & Clients
Key Customers
Dentists and dental practices.
Geographic Presence
How vVARDIS competes
Competitive Advantages
- No drilling or injections
- Exclusive US distribution with Henry Schein
How vVARDIS grows
Growth Strategy
International commercial expansion, funded partly through the listing.
Distribution Model
B2B sales through dental distributors.
Regulatory Context
Products subject to medical-device approvals in each market; the US offering is subject to SEC rules.
Key Risks
- Clinical adoption
- Dependence on one distributor
- Post-IPO execution
Strategic Insights
- Pricing below the range shows how selective the IPO market is.
- The exclusive distribution deal with Henry Schein accelerated US adoption.
Funding & Investors
Latest Valuation
Funding Rounds
- 2026 - Investimento strategico: Non divulgato
Lead: Apollo - 2025 - Funding round: $50M
Lead: OrbiMed - 2025 - Funding round: $35M
Lead: OrbiMed
Key Investors
Founding Team
Founders
Key Metrics
Lessons from vVARDIS
- Access to public markets also depends on the price investors are willing to pay.
Similar Startups
Nouscom
A biotech headquartered in Basel with operations in Rome developing viral-vector immunotherapies against tumour neoantigens; its lead candidate is NOUS-209.
Read AnalysisNewAmsterdam Pharma
Biopharmaceutical company focused on innovative therapies for hypercholesterolemia and cardiometabolic diseases with breakthrough clinical results.
Read AnalysisMindMaze
Founded in Lausanne in 2012, it is now part of the listed group MindMaze Therapeutics (SIX: MMTX) after the December 2025 combination with Relief. It is no longer a private unicorn.
Read AnalysisSources
- vVARDIS Announces Pricing of Initial Public Offering — vVARDIS / Business Wire
- Apollo investment supports vVARDISโs global Curodont expansion — Dental Tribune
- vVARDIS: Apollo investment confirms unicorn status — Pulse 2.0
- Cavity treatment provider vVARDIS sets terms for $214 million US IPO — Renaissance Capital